New Delhi: Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump’s move to impose 100 per cent import tariffs on pharmaceutical
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump’s move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
Reacting to the development, IPA Secretary General Sudarshan Jain said in a statement, “It is not applicable to generics medicines.”
Trump’s statement refers to patented and branded products supplied to US, he added.
In his post on social media platform Truth Social, Trump wrote, “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America.”
The US President further clarified, “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.
